Uniphar plc (UPR) Fair Value & Analysis

Healthcare · IE · Market cap €1.3B

A solid business, but screening 22% overvalued on our models.

What matters now

• The model range is unusually wide (€1.91 to €5.41). The outcome hinges heavily on assumptions, so read the point estimate with caution.
• Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.

How to read this chart

60‑month range €1.93 – €4.96 · fair‑value band €1.91 – €5.41 · the €4.74 price screens above the €3.71 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Uniphar plc (UPR) currently trades at €4.74, while our model-based Fair Value estimate is €3.71, implying the stock looks roughly 21.7% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Uniphar plc generated revenue of €3.1B at a net margin of 1.7%. Revenue grew 13.3% year over year. It earns a return on equity of 12.7%. Net debt stands at €171M. Fundamentals as of Jul 21, 2026

Our scenario range runs from €1.91 (bear case) to €5.41 (bull case); at €4.74, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 5% below its 52-week high and 40% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at -22%, UPR screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples (€3.92) versus Dividend Discount (€0.2500). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Uniphar plc, together with its subsidiaries, operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally. It operates through three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail.

Full company description

Uniphar plc, together with its subsidiaries, operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally. It operates through three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail. The company provides sales, marketing, servicing, quality, compliance, regulatory support, and distribution services to medical device manufacturers; high-value services across the life cycle of a pharmaceutical product; and healthcare professionals with access to medicines that cannot source through traditional channels. It is also involved in the pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals and veterinary surgeons; operates a network of pharmacies under the Life, Allcare, Hickey's, and McCauley brands. In addition, the company provides pharmacy support, pharmaceutical supply chain and services, medical device distribution, specialist nursing and infusion, outsourcing and resourcing, healthcare technology, medical affairs, online pharmacy and product fostering, pharmaceutical wholesale distributor, retail pharmacy software and technology, and telecommunications support services, as well as specialist provider of pharmaceuticals. Uniphar plc was founded in 1967 and is headquartered in Dublin, Ireland.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Uniphar plc reported revenue of €3.1B in FY2025 versus €1.9B in FY2021, a compound +12.2%/yr. Reported net income was €51.1M in FY2025, compounding +1.5%/yr from FY2021.

UPR screens 22% overvalued. Compare with McKesson Corporation →

Peer Group

Medical Distribution · 81 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Distribution median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.